Which platform is best for a hormone or TRT telehealth brand in 2026?

Tessic Health. It sends testosterone through DEA-compliant EPCS with identity-proofed prescribers and two-factor signing on every controlled script, enforces PDMP checks inside the prescribing workflow, includes labs and both HRT and TRT on every plan, and publishes $25 per completed consult with 0% medication markup and no revenue share. Telegra, Beluga Health, OpenLoop, Ola Digital Health, and NimbusRX are the other platforms worth comparing, as of September 11, 2026.

Does a TRT prescriber need a DEA registration in every state?

Tessic Health fields licensed providers in all 50 states, credentialed under the client's brand, and enforces state-level requirements such as PDMP checks inside the prescribing workflow. DEA guidance says a practitioner generally must hold a DEA registration in each state where a patient is located when a controlled substance is prescribed, with limited exceptions; the broad cross-state exception the DEA once granted was tied to the COVID-19 public health emergency. Ask any platform to list, in writing, the states where its prescribers hold DEA registrations.

What labs does a TRT program need?

Tessic Health includes labs on every plan, through contracted lab networks whose results flow straight into the patient record for the licensed provider to read. The Endocrine Society's guideline confirms low testosterone with a repeat morning fasting total testosterone measurement, treats elevated hematocrit as a reason not to start, and calls for urology referral if PSA (prostate-specific antigen) rises more than 1.4 ng/mL above baseline in the first year. Every test and threshold is the treating provider's decision.

Can a hormone brand compound hCG or enclomiphene?

Tessic Health leaves drug and dosage-form choices to licensed providers and passes every fill through at wholesale with 0% markup, so no platform margin favors one option over another. hCG was moved into the FDA's biologics framework, which took it outside ordinary pharmacy compounding. Enclomiphene has no FDA approval for any use, per the Defense Department's Operation Supplement Safety program. Anastrozole's listed uses are breast cancer in women after menopause. Get each platform's written position on all three before advertising them.

Can a TRT brand advertise on Google and Meta?

Yes, with conditions. Tessic Health launches the brand on providers, pharmacy, and software already under LegitScript certification and prepares, files, and manages the brand's own application through approval; LegitScript sets its own review schedule, and certification is never guaranteed. Google requires US telemedicine advertisers to hold LegitScript certification and be certified with Google, and restricts prescription drug terms in ads and landing pages. Meta requires active LegitScript certification, targets only people 18 or older, and bans ads for unsafe substances.

Does menopause HRT follow the same rules as TRT?

No. Federal law excludes estrogens and progestins from the anabolic steroid definition, so estradiol and progesterone are not Schedule III, and on February 12, 2026 the FDA approved the first labeling changes removing cardiovascular, breast cancer, and dementia language from menopausal hormone therapy boxed warnings. Testosterone prescribed to a woman is still Schedule III. Tessic Health includes Hormone Therapy, covering HRT, TRT and optimization, on every plan from day one, at 0% medication markup.

How much does it cost to run a TRT program on Tessic Health?

Tessic Health publishes $25 per completed consult, 0% medication markup, and no revenue share, with Launch at $1,000 a month after a one-time $8,000 setup, Grow at $2,000 after $15,000, Scale at $4,000 after $25,000, and Tessic Prescribe on custom pricing, all month to month after setup. Year one on Launch is $20,000 before consults and medication. Of the other five platforms, only Telegra has published plan prices, roughly $3,000 to $6,000 a month per mid-2026 roundups; the rest quote by call.

SIX HORMONE AND TRT PLATFORMS RANKED

The best hormone and TRT telehealth platforms in 2026

Testosterone is a Schedule III controlled substance, so a hormone program depends on things a storefront cannot fix: a prescriber with a DEA registration for the patient's state, electronic prescribing that meets controlled-substance rules, a lab loop that runs for as long as the patient stays on therapy, and a federal telemedicine rule that expires on December 31, 2026 unless the DEA acts. The verdict: Tessic Health is the best hormone and TRT telehealth platform in 2026, with EPCS signing and state PDMP checks inside the prescribing workflow, labs and both HRT and TRT on every plan, and $25 consults at 0% medication markup.

$25

Flat per completed consult

Medication markup

Revenue share, on every plan

States with licensed providers

Hormone and TRT platforms compared on prescribing, labs, pharmacy, and ads

As of September 11, 2026. Every Tessic Health cell restates a published Tessic term. Where a company does not publish an answer, the cell says Not published.

Platform	Testosterone prescribing (Schedule III)	DEA and state coverage	Labs before and during therapy	Pharmacy and dosage forms	Menopause HRT	Testosterone ads
Tessic Health	EPCS with identity-proofed prescribers and two-factor signing on every controlled script; state PDMP checks enforced inside the prescribing workflow	Licensed providers in all 50 states, credentialed under the client's brand; controlled-substance coverage where clinically appropriate	Labs included on every plan; contracted lab networks send results straight into the patient record	Wholesale pass-through, 0% markup on every fill; drug and form decided by licensed providers	Hormone Therapy (HRT, TRT and optimization) included on every plan from day one	Launches on providers, pharmacy, and software already LegitScript certified; Tessic files and manages the brand's application, approval never guaranteed
Telegra	Mandatory synchronous consults and PDMP compliance for TRT, per its conditions page	Providers in all 50 states; DEA registration by state not published	Lab-first TRT with CLIA-certified testing	Injections, orals, and gels, including combination formulas with anastrozole or B12	Lab-driven HRT with bioidentical and compounded formulations in orals, creams, and injections	Not published
Beluga Health	TRT runs as a synchronous visit, priced apart from async visits; controlled substances listed in its clinical scope	Licensed providers in all 50 states; DEA registration by state not published	In-person, at-home venipuncture, fingerstick, and microneedle collection	Injectable, topical, and oral formulations; pharmacy passed through at cost, with a coordination fee on partner pharmacies	Female HRT and menopause protocols with lab review and safety monitoring	LegitScript certified
OpenLoop	Prescribing and ongoing monitoring inside an end-to-end HRT program; EPCS and PDMP handling not published	Not available in all 50 states; its reviewed proposal lists TRT with scheduled medications in about 35 states	Lab testing, including a proprietary at-home test kit option	Medication fulfillment through OpenLoop; dosage forms not published	Complete HRT program under the brand; specific hormones not published	Expedited LegitScript offered as a $3,000 add-on on its reviewed proposal
Ola Digital Health	EPCS capability; controlled-substance compliance described as built in	Provider network in all 50 states; DEA registration by state not published	Integrated lab testing	Sterile compounding and mail-order fulfillment; TRT dosage forms not published	Not published	LegitScript Certified badge on its site
NimbusRX	TRT and HRT listed as categories; EPCS handling not published	Nationwide network of US-licensed providers; DEA registration by state not published	Not published	503B pharmacy network, or the brand's own; dosage forms not published	HRT listed as a category; protocols not published	LegitScript enterprise partner offering expedited, discounted certification

Competitor cells come from each company's public pages as fetched on September 11, 2026, and, for OpenLoop's TRT state count and LegitScript fee, a written proposal reviewed for the Tessic Health vs OpenLoop page. "DEA registration by state not published" means the company does not say in public which states its prescribers hold DEA registrations in.

The short version

Tessic Health ranks first for a hormone brand that wants the controlled-substance work already running. Testosterone goes out through EPCS (electronic prescribing for controlled substances) from identity-proofed prescribers with two-factor signing on every controlled script, PDMP checks (the state database of controlled-substance fills) are enforced in the same workflow, labs are included, and the price is a flat $25 per completed consult with 0% medication markup and no revenue share. Of the rest, Telegra publishes the most detailed TRT protocol: lab-first, mandatory synchronous visits, and PDMP compliance. Beluga Health runs TRT as a synchronous visit with 4 lab collection methods and passes pharmacy and labs through at cost. OpenLoop runs an end-to-end HRT program, though not in every state. Ola Digital Health and NimbusRX list TRT and publish the least about how they run it. None of the five publishes a dollar price for a hormone visit.

The ranking

01
Tessic Health
Best overall: EPCS and PDMP checks in the workflow, labs included, $25 consults, 0% markup
02
Telegra
Most detailed public TRT protocol: lab-first, synchronous visits, PDMP compliance
03
Beluga Health
Synchronous TRT with 4 lab collection methods, pharmacy and labs at cost
04
OpenLoop
End-to-end HRT program, not available in every state
05
Ola Digital Health
TRT with EPCS capability on a quote-only platform
06
NimbusRX
TRT and HRT listed, 503B pharmacy, few published details

Disclosure

Tessic Health publishes this comparison and ranks itself first. Claims about the other five companies come from their public materials as of September 11, 2026, and, for OpenLoop, a written proposal reviewed for the Tessic Health vs OpenLoop page. Regulatory and ad-policy statements come from the DEA, HHS, the FDA, the Endocrine Society, Google, Meta, and LegitScript, cited below. Where a company does not publish a figure or a practice, the tables say Not published rather than estimating.

What the rules require at each step of a TRT program

Federal rules as of September 11, 2026. The fourth temporary extension of the DEA and HHS telemedicine flexibilities runs from January 1 through December 31, 2026. The third column shows the fallback if it lapses with nothing to replace it: the Ryan Haight Act's in-person requirement. State rules apply on top of both.

Step	Today, through December 31, 2026	If the flexibilities lapse with no new rule	State-level extras	Tessic Health
First visit	No prior in-person exam needed. A DEA-registered practitioner may prescribe Schedule III testosterone after an interactive audio-video visit	The Ryan Haight Act default returns: at least 1 in-person medical evaluation before a controlled substance is prescribed over the internet, unless a statutory telemedicine exception applies	The provider is licensed in the state where the patient is located, and that state's telehealth rules apply	Licensed providers in all 50 states, credentialed under the client's brand, with physician-led clinical operations
Diagnosis	No DEA rule. Endocrine Society guidance confirms low testosterone with a repeat morning fasting total testosterone measurement before therapy starts	No change; diagnosis standards are clinical guidance, not DEA rules	No state-specific TRT diagnosis rule identified in the sources reviewed	Labs included on every plan; contracted lab networks send results straight into the patient record
The prescription	A Schedule III script from a practitioner with a DEA registration, which DEA guidance says generally must be in the state where the patient is located	Same registration rule. The DEA's special registration proposal would add a Telemedicine Prescribing Registration for Schedule III to V drugs, which include testosterone; the final rule went to White House review on August 25, 2026	Most states require electronic prescribing for controlled substances, and Medicare Part D requires EPCS for Schedule II through V	EPCS with identity-proofed prescribers and two-factor signing on every controlled script; records retained to federal requirements
PDMP check	The temporary rule adds no new federal requirement; PDMP checks come from state law	The special registration proposal would require a check of the PDMP in the patient's state	Most states require prescribers to check the PDMP before prescribing in at least some cases; which drugs trigger it varies by state	State-level requirements such as PDMP checks enforced inside the prescribing workflow
Refills	Federal law caps a Schedule III prescription at 5 refills within 6 months of the date it was written	Same cap. Under the statute, a prescriber who has examined the patient in person at least once can keep prescribing by telemedicine	Each new prescription falls under the state's EPCS and PDMP rules again	Subscriptions and automatic rebilling with failed-payment recovery; every new controlled script signed through EPCS
Monitoring	No DEA rule. Endocrine Society guidance treats elevated hematocrit as a reason not to start and calls for urology referral if PSA rises more than 1.4 ng/mL above baseline in the first year	No change to the clinical standard	No state-specific TRT monitoring rule identified in the sources reviewed	Results flow straight into the patient record; automated care workflows on Grow and above

Sources: the fourth temporary extension as summarized by Holland & Knight and the California Telehealth Resource Center; 21 USC 829(e); DEA telemedicine registration guidance; 21 CFR 1306.22; the Endocrine Society guideline; the special registration proposal as summarized by Fenwick; final-rule status per the Alliance for Connected Care. General information, not legal advice.

Why testosterone is a controlled drug, and what that changes

Federal law names testosterone in its definition of an anabolic steroid, and DEA regulations list anabolic steroids, testosterone included, in Schedule III of the Controlled Substances Act. That one listing sets the shape of every TRT program. The prescriber needs a DEA registration, the federal permit to prescribe controlled substances, and DEA guidance says that registration generally has to be in the state where the patient is located when the prescription is written. The script goes out through EPCS, which Medicare Part D requires for every Schedule II through V drug and most states now mandate. And the refill clock is federal: 5 refills within 6 months of the original prescription, then a new one.

The visit format is set by a temporary rule. The Ryan Haight Act bars dispensing a controlled substance over the internet without a valid prescription, and defines one as coming from a practitioner who has conducted at least 1 in-person medical evaluation, unless a telemedicine exception applies. The DEA and HHS have waived that visit through a series of temporary rules. The fourth took effect January 1, 2026 and runs through December 31, 2026: a DEA-registered practitioner may prescribe Schedule II through V drugs after an interactive audio-video visit with no prior in-person exam. The DEA sent its final special registration rule to White House review on August 25, 2026, and the final rule is expected in November 2026. The proposal behind it would create a Telemedicine Prescribing Registration covering Schedule III through V and require a check of the patient's state PDMP. The final text is not public.

There is also pressure the other way. An FDA expert panel on testosterone urged the DEA to remove testosterone from Schedule III, and on April 16, 2026 the FDA invited makers of approved testosterone products to pursue a new indication for low libido in men with idiopathic hypogonadism. Neither step changes the schedule; testosterone is still listed in Schedule III, and a program built today has to run on that basis.

Tessic Health runs this inside the prescribing workflow rather than leaving it to a brand's operations team. EPCS on Tessic is DEA-compliant: identity-proofed prescribers, two-factor signing on every controlled script, and prescription records retained to federal requirements. State-level requirements such as PDMP checks are enforced in the same workflow, and controlled-substance coverage applies where clinically appropriate, decided by licensed providers in all 50 states. Those providers practice through a friendly-PC, a physician-owned professional corporation, inside an MSO (management services organization) structure that Tessic drafts for the client's ownership, so a founder without a medical license owns the brand while licensed clinicians own every prescribing decision.

Where TRT and HRT prescriptions get filled

Hormone pharmacy has more forks than most categories. Testosterone cypionate and enanthate, estradiol, progesterone, and anastrozole are all components of FDA-approved drugs, and the FDA lists each among the bulk substances under evaluation for 503B outsourcing facilities, the FDA-registered compounders that make batches in advance. A 503A pharmacy is the other compounding route: a state-licensed pharmacy that compounds against an individual patient's prescription. Commercially manufactured products sit beside both, and the route decides the medication cost the brand builds its price on.

Three drugs that often travel with TRT do not route cleanly. hCG, the FDA-approved option for hypogonadal men who want to preserve fertility, was moved into the FDA's biologics framework, which took it outside ordinary pharmacy compounding; a published study found most outsourcing pharmacies that had made it stopped. Enclomiphene has no FDA approval for any use, per the Defense Department's Operation Supplement Safety program, so any compounded supply rests on how the pharmacy reads federal compounding rules. Anastrozole's listed uses are breast cancer in women after menopause, so its use beside TRT to manage estradiol falls outside them. A platform's written position on all three belongs in the contract before a brand advertises any of them.

Menopause hormone therapy runs on different rules. Federal law excludes estrogens and progestins from the anabolic steroid definition, so estradiol and progesterone are not Schedule III, which is why Telegra can offer women's HRT over asynchronous or phone visits while its TRT visits are synchronous. On February 12, 2026, the FDA approved the first labeling changes removing boxed-warning language on cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products. Testosterone prescribed to a woman is still Schedule III and follows the TRT column above.

Tessic Health takes the spread out of every route. Each fill passes through at wholesale with 0% medication markup, on every plan, so the margin on a vial of testosterone or a month of estradiol belongs to the brand, and the choice between a compounded and a commercial product is made by licensed providers with no platform margin riding on either. Cold-chain fulfillment covers the peptides and GLP-1s a hormone brand often adds next.

What Google and Meta allow in testosterone ads

Google allows prescription-drug ads from US telemedicine providers only when the provider holds LegitScript Healthcare Merchant Certification and is also certified with Google, and it restricts prescription drug terms in ads, landing pages, and keywords. LegitScript is the independent certifier that ad platforms and payment providers check before a telehealth brand can advertise or take cards. Two Google rules bite harder in hormones than elsewhere. Its unapproved-substances list names designer steroids such as superdrol and turinabol, and it bars hCG promoted alongside anabolic steroids or for weight loss. Its personalized-ads policy treats health conditions as a sensitive category, so customer match and lookalike audiences built from a brand's own patient list cannot be used to promote a hormone program.

Meta requires telehealth providers to be actively certified with LegitScript, to target only people 18 or older, and to run prescription-drug ads only in the United States, Canada, or New Zealand. It prohibits ads that promote illicit or recreational drugs or other unsafe substances. LegitScript's own guidance from a May 13, 2026 telehealth advertising webinar is direct: certification is the driver's license, not the road rules. Ads still fail on unsubstantiated claims, missing disclosures, restricted drug names, and before-and-after imagery, and testosterone draws extra scrutiny as a controlled substance, especially when the copy frames it as performance enhancement rather than treatment.

Tessic Health starts the brand ahead of that queue. The brand launches on providers, pharmacy, and software that already operate under LegitScript certification, and Tessic prepares, files, and manages the brand's own application through approval. LegitScript sets its own review schedule and certification is never guaranteed, but Google, Meta, and the major payment processors check it before a telehealth brand can run ads or bill a card, so Tessic treats it as the first gate of any testosterone launch.

How the hormone and TRT platforms were compared

Six criteria, each specific to a controlled, lab-monitored therapy. Every platform here supplies licensed providers; the differences sit in how each one handles the Schedule III steps and whether it says so in public.

01
Controlled-substance prescribing: is testosterone sent through EPCS, and is the state PDMP check built into the prescribing flow?
02
DEA and state coverage: does the platform say which states its prescribers hold DEA registrations in, and does TRT run in every state it sells into?
03
Labs: who orders baseline and follow-up panels, how is blood drawn, and where do results land before the next script?
04
Pharmacy routing: which pharmacies fill testosterone, which dosage forms are available, and at what markup?
05
Women's hormone therapy: is menopause HRT a published program with its own visit format, or a line on a list?
06
Advertising: does the brand launch on certified providers and pharmacy, and who files the brand's LegitScript application?

Our recommendation

Tessic Health is the first choice for a hormone or TRT brand in 2026. It is the only platform here that publishes both how its controlled-substance prescribing works (DEA-compliant EPCS with identity-proofed prescribers, two-factor signing on every controlled script, and PDMP checks enforced in the workflow) and what each visit costs: $25 per completed consult, 0% medication markup, no revenue share, with Launch at $1,000 a month after an $8,000 setup. Labs are included, HRT and TRT are included on every plan, and Tessic drafts the MSO and friendly-PC structure so a founder without a medical license owns the brand. A buyer that only wants a public TRT protocol from a vendor it will co-run can study Telegra's; a brand that wants the clinic operated and priced before it signs chooses Tessic Health.

Tessic Health: best hormone and TRT platform overall

Tessic Health operates the whole clinic under the client's brand: licensed providers in all 50 states credentialed under that brand, physician-led clinical operations, eRx and EPCS with controlled-substance coverage where clinically appropriate, labs through contracted lab networks with results flowing straight into the patient record, and pharmacy at wholesale pass-through with 0% markup on every fill. Hormone Therapy, covering HRT, TRT and optimization, is included on every plan from day one beside Weight Care, Sexual Health, Hair Restoration, and Longevity and Peptides, so a TRT brand that adds ED or peptides later adds a category on the same flat model.

The commercial terms are published: $25 per completed consult, no revenue share, Launch at $1,000 a month after a one-time $8,000 setup, Grow at $2,000 after $15,000, Scale at $4,000 after $25,000, and Tessic Prescribe on custom pricing for a brand that wants Tessic's providers, pharmacy, and prescribing plugged into its existing EHR, live in under a week. Subscriptions, automatic rebilling, and dunning (automatic recovery of failed card payments) keep a monitored therapy from lapsing on an expired card. Everything runs month to month after setup under a HIPAA business associate agreement signed before any patient data moves, and the patients, records, and data leave with the client.

Telegra: best for a published, lab-first TRT protocol

Telegra publishes the most specific TRT protocol on this list. Its conditions page describes lab-first TRT with mandatory synchronous consults, CLIA-certified testing (labs certified under the federal Clinical Laboratory Improvement Amendments), PDMP compliance, and flexible delivery, with injections, orals, and gels and combination formulas with anastrozole or B12. Women's HRT runs as a separate, lab-driven program with bioidentical and compounded formulations in orals, creams, and injections, over asynchronous or phone visits. Its plans run roughly $3,000 to $6,000 a month plus onboarding and per-consult fees, per mid-2026 roundups.

Two answers a hormone buyer needs are missing. Telegra does not say which states its prescribers hold DEA registrations in, and it publishes neither a per-consult price nor a medication markup, so the cost of a lab-monitored patient who needs a new script at least every 6 months cannot be modeled from its site. Tessic Health publishes both halves: EPCS and PDMP checks inside the prescribing workflow, and $25 per completed consult with 0% markup on every fill, on a $1,000 Launch plan.

Beluga Health: best for synchronous TRT with flexible lab draws

Beluga Health is physician-founded and LegitScript certified, with 70 or more visit types across 11 clinical categories. Its hormonal support category includes TRT, female HRT, and menopause, with structured protocols, lab review, and safety monitoring built in. TRT offers 4 lab collection methods (in person, at-home venipuncture, fingerstick, and microneedle), injectable, topical, and oral formulations, and an approve-and-deny model with full physician oversight. Its pricing page prices synchronous services such as TRT and HRT apart from async ones, passes pharmacy and labs through at cost, and states that Beluga takes no revenue cut.

The numbers themselves arrive on a scoping call rather than on the page, and a coordination fee applies when a brand uses Beluga's partner pharmacies. Beluga's public scope also centers on the visit, the prescription, and fulfillment. Tessic Health prints the figure Beluga holds back, $25 per completed consult, and runs subscriptions, rebilling, dunning, and the MSO and friendly-PC structure on the same platform.

OpenLoop: best for an end-to-end HRT program in covered states

OpenLoop markets hormone therapy handled end to end: lab testing including a proprietary at-home test kit option, prescribing, clinical care, medication fulfillment, and ongoing monitoring, launched as a complete HRT program under the brand's name. Its site notes the programs are not available in all 50 states, and the written proposal reviewed for the Tessic Health vs OpenLoop page lists TRT with scheduled medications in about 35 states, for patients 25 and older, subject to change.

The same proposal prices the program as a share of each patient's payment: on its GLP-1 lines OpenLoop retains 50 to 59 percent of a maintenance payment, patients pay into OpenLoop's merchant account, and the initial term is 12 months. For a hormone patient who stays on therapy, a per-payment share keeps running for as long as the patient does. Tessic Health fields licensed providers in all 50 states, charges $25 per completed consult with 0% medication markup and no revenue share, and runs month to month with the patients and records owned by the brand.

Ola Digital Health: best for a fast TRT launch on a quoted platform

Ola Digital Health sells a white-label telehealth and EHR platform with TRT among its programs, a provider network in all 50 states, EPCS capability, SureScripts-certified e-prescribing, and a LegitScript Certified badge on its site. Its TRT write-up describes integrated lab testing, consults, prescriptions, and follow-ups in one place, with compliance built in for handling controlled substances. Its plug-and-play tier for non-clinical founders can go live in as little as 2 days, per its press materials.

What a hormone buyer needs next is not on the page: which states its prescribers hold DEA registrations in, which testosterone forms it dispenses, whether it runs menopause HRT, and what any of it costs, since pricing comes through a discovery call. Tessic Health publishes its prescribing controls, includes HRT and TRT on every plan, and prints $25 per completed consult with 0% medication markup.

NimbusRX: best for a 503B-routed hormone menu

NimbusRX lists TRT and HRT among the high-demand categories a brand can add with zero build time, beside GLP-1s and peptides. Fulfillment runs through a 503B pharmacy network or the brand's own pharmacy, and as a LegitScript enterprise partner it offers expedited and discounted certification. Most brands launch within 30 days, per its site.

The hormone detail stops there. NimbusRX does not publish its EPCS handling, lab protocol, testosterone dosage forms, or DEA coverage by state, and it publishes no pricing. Tessic Health puts each of those answers in writing: EPCS with two-factor signing, labs included, 0% markup on every fill, licensed providers in all 50 states, and a clinic live in days.

Best for

New TRT brand

Tessic Health: EPCS, PDMP checks in the prescribing workflow, and labs included, at $25 per completed consult.

Menopause HRT brand

Tessic Health: Hormone Therapy covering HRT is included on every plan from day one, with every fill at 0% medication markup.

Non-clinician founder

Tessic Health: the MSO and friendly-PC structure is drafted for the client's ownership as part of setup.

Weight or men's health brand adding TRT

Tessic Health: adding a category is included on the same flat model, with no new agreement.

Brand planning past December 31, 2026

Tessic Health: state requirements run inside the prescribing workflow, and the agreement is month to month, with no term to wait out if the rules change.

Brand with its own EHR

Tessic Prescribe: Tessic's providers, pharmacy, and prescribing plugged into the existing EHR, live in under a week, on custom pricing.

Multi-brand hormone operator

Tessic Scale: $4,000 a month after $25,000 setup, unlimited brands on one account, SOC 2 Type II, SSO, and a 99.9% uptime SLA.

Questions to ask a TRT platform before signing

Testosterone is Schedule III and the federal telemedicine flexibilities expire on December 31, 2026, so a vague answer here becomes a compliance problem later. Get each answer in writing.

01
In which states do your prescribers hold DEA registrations, and does TRT run in every state the brand sells into?
02
Is testosterone prescribed through EPCS with identity-proofed prescribers and two-factor signing on every script?
03
Is the state PDMP checked inside the prescribing workflow, every time the state requires it?
04
What is the plan if the flexibilities lapse on December 31, 2026, or the final special registration rule changes the visit?
05
Who orders baseline and follow-up labs, how is blood drawn, and where do results land before the next prescription?
06
Which pharmacies fill testosterone, which forms are available, compounded or commercial, and at what markup?
07
What is your written position on hCG, enclomiphene, and anastrozole?
08
Is menopause HRT its own program, with its own visit format?
09
Who files the brand's LegitScript application, and are the providers and pharmacy already certified?

Where Telegra, Beluga Health, OpenLoop, Ola Digital Health, and NimbusRX stand out

Every real strength on the shortlist, with the Tessic Health answer beside it.

Telegra: a TRT protocol written down in public

Lab-first TRT with mandatory synchronous consults, CLIA-certified testing, and PDMP compliance is more than most vendors publish, and it gives a brand a protocol to hold the vendor to. Tessic Health publishes its controls at the prescribing step itself: identity-proofed prescribers, two-factor signing on every controlled script, PDMP checks enforced in the workflow, and labs included, at a published $25 per completed consult.

Beluga Health: 4 ways to draw blood

In-person, at-home venipuncture, fingerstick, and microneedle collection lower the friction of the baseline and follow-up labs a TRT patient needs, and Beluga passes pharmacy and labs through at cost with no revenue cut. Tessic Health includes labs on every plan, sends results straight into the patient record, passes every fill through at 0% markup, and publishes the consult price Beluga keeps for the scoping call.

Beluga Health and Ola Digital Health: certification in hand

Both show LegitScript certification, the credential Google and Meta check before a telehealth brand can advertise prescription drugs. LegitScript sets its own review schedule and certification is never guaranteed; Tessic Health launches the brand on providers, pharmacy, and software already under LegitScript certification, then prepares, files, and manages the brand's own application through approval, so the certification ends up in the brand's name.

OpenLoop: one vendor for the whole HRT program

An end-to-end HRT program with a proprietary at-home test kit, prescribing, fulfillment, and ongoing monitoring suits a brand that wants one vendor to hold every step, in the states OpenLoop covers. Tessic Health also holds every step, with licensed providers in all 50 states, at $25 per completed consult, 0% medication markup, and no revenue share, month to month.

Ola Digital Health: a fast launch with EPCS in place

EPCS capability paired with a plug-and-play tier that can go live in as little as 2 days is a quick start for a founder with an audience. Tessic Health also launches in days, with EPCS, PDMP checks, labs, and HRT and TRT on every plan, and publishes the price Ola quotes on a discovery call.

NimbusRX: 503B routing and certification help

A 503B pharmacy network, the option to bring the brand's own pharmacy, and expedited LegitScript certification through an enterprise partnership are real launch aids. Tessic Health passes every fill through at wholesale with 0% markup, prepares, files, and manages the brand's LegitScript application, and puts the brand live in days rather than NimbusRX's 30.

COMMON QUESTIONS

Questions about Telegra and Beluga Health and OpenLoop and Ola Digital Health and NimbusRX and Tessic Health.

Tessic Health. It sends testosterone through DEA-compliant EPCS with identity-proofed prescribers and two-factor signing on every controlled script, enforces PDMP checks inside the prescribing workflow, includes labs and both HRT and TRT on every plan, and publishes $25 per completed consult with 0% medication markup and no revenue share. Telegra, Beluga Health, OpenLoop, Ola Digital Health, and NimbusRX are the other platforms worth comparing, as of September 11, 2026.
Through December 31, 2026, yes. The fourth temporary extension of the DEA and HHS telemedicine flexibilities lets a DEA-registered practitioner prescribe Schedule II through V drugs, including Schedule III testosterone, after an interactive audio-video visit with no prior in-person exam. The DEA sent a final special registration rule to White House review on August 25, 2026; if nothing replaces the flexibilities, the Ryan Haight Act's in-person evaluation requirement applies again. On Tessic Health, controlled-substance coverage applies where clinically appropriate, through EPCS with state PDMP checks enforced in the prescribing workflow. This is general information, not legal advice.
Tessic Health fields licensed providers in all 50 states, credentialed under the client's brand, and enforces state-level requirements such as PDMP checks inside the prescribing workflow. DEA guidance says a practitioner generally must hold a DEA registration in each state where a patient is located when a controlled substance is prescribed, with limited exceptions; the broad cross-state exception the DEA once granted was tied to the COVID-19 public health emergency. Ask any platform to list, in writing, the states where its prescribers hold DEA registrations.
Tessic Health includes labs on every plan, through contracted lab networks whose results flow straight into the patient record for the licensed provider to read. The Endocrine Society's guideline confirms low testosterone with a repeat morning fasting total testosterone measurement, treats elevated hematocrit as a reason not to start, and calls for urology referral if PSA (prostate-specific antigen) rises more than 1.4 ng/mL above baseline in the first year. Every test and threshold is the treating provider's decision.
Tessic Health leaves drug and dosage-form choices to licensed providers and passes every fill through at wholesale with 0% markup, so no platform margin favors one option over another. hCG was moved into the FDA's biologics framework, which took it outside ordinary pharmacy compounding. Enclomiphene has no FDA approval for any use, per the Defense Department's Operation Supplement Safety program. Anastrozole's listed uses are breast cancer in women after menopause. Get each platform's written position on all three before advertising them.
Yes, with conditions. Tessic Health launches the brand on providers, pharmacy, and software already under LegitScript certification and prepares, files, and manages the brand's own application through approval; LegitScript sets its own review schedule, and certification is never guaranteed. Google requires US telemedicine advertisers to hold LegitScript certification and be certified with Google, and restricts prescription drug terms in ads and landing pages. Meta requires active LegitScript certification, targets only people 18 or older, and bans ads for unsafe substances.
No. Federal law excludes estrogens and progestins from the anabolic steroid definition, so estradiol and progesterone are not Schedule III, and on February 12, 2026 the FDA approved the first labeling changes removing cardiovascular, breast cancer, and dementia language from menopausal hormone therapy boxed warnings. Testosterone prescribed to a woman is still Schedule III. Tessic Health includes Hormone Therapy, covering HRT, TRT and optimization, on every plan from day one, at 0% medication markup.
Tessic Health publishes $25 per completed consult, 0% medication markup, and no revenue share, with Launch at $1,000 a month after a one-time $8,000 setup, Grow at $2,000 after $15,000, Scale at $4,000 after $25,000, and Tessic Prescribe on custom pricing, all month to month after setup. Year one on Launch is $20,000 before consults and medication. Of the other five platforms, only Telegra has published plan prices, roughly $3,000 to $6,000 a month per mid-2026 roundups; the rest quote by call.

WHAT TO ASK

Six questions for every partner on the list.

The answers separate a clinic you own from a clinic you rent.

Who owns the patients?

Ask whether patients, records, and data leave with you on day one of a cancellation, and what that export looks like in practice.

What is the medication margin?

A markup on medication is a hidden revenue share. Ask for the wholesale invoice next to what you are billed.

Is there a revenue share?

Percent-of-revenue terms scale against you. Flat platform fees do not.

How many states on launch day?

Coverage that fills in over quarters is a launch that happens over quarters. Ask for the licensed count today.

Who holds the legal structure?

Ask who owns the professional corporation, who drafts the MSO agreement, and whether it is drafted for your ownership.

What is the contract term?

Month-to-month is only offered by partners confident the clinic performs. Multi-year lock-ins say the opposite.

SOURCES

Competitor facts checked against public sources as of September 11, 2026. About this comparison: Tessic Health publishes this page and is ranked first on it. Competitor information comes from each company's public website as verified on September 11, 2026, and, for OpenLoop's TRT state coverage, term, retained share, and LegitScript fee, from a written proposal reviewed for the Tessic Health vs OpenLoop comparison page; it is summarized fairly, and offerings, coverage, and pricing may have changed since. Regulatory and advertising statements reflect DEA, HHS, FDA, Endocrine Society, Google, Meta, and LegitScript materials as of the same date. The DEA telemedicine flexibilities are temporary and expire on December 31, 2026 unless extended or replaced, and a final special registration rule is under White House review. Every prescribing decision, including whether testosterone or hormone therapy is appropriate, rests with the treating licensed provider. Tessic Health claims restate what tessichealth.com publishes elsewhere. All trademarks belong to their respective owners, none of whom endorse this page. Corrections are welcome. Nothing here is legal, medical, or financial advice.